Next Article in Journal
The Regulatory Role of KIBRA and PTPN14 in Hippo Signaling and Beyond
Next Article in Special Issue
Telomerase Activity is Downregulated Early During Human Brain Development
Previous Article in Journal
The Roles of NDR Protein Kinases in Hippo Signalling

Telomere and Telomerase Therapeutics in Cancer

Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
Author to whom correspondence should be addressed.
Academic Editor: Gabriele Saretzki
Received: 22 April 2016 / Revised: 18 May 2016 / Accepted: 20 May 2016 / Published: 26 May 2016
(This article belongs to the Special Issue Telomerase Activity in Human Cells)
Telomerase is a reverse transcriptase capable of utilizing an integrated RNA component as a template to add protective tandem telomeric single strand DNA repeats, TTAGGG, to the ends of chromosomes. Telomere dysfunction and telomerase reactivation are observed in approximately 90% of human cancers; hence, telomerase activation plays a unique role as a nearly universal step on the path to malignancy. In the past two decades, multiple telomerase targeting therapeutic strategies have been pursued, including direct telomerase inhibition, telomerase interference, hTERT or hTERC promoter driven therapy, telomere-based approaches, and telomerase vaccines. Many of these strategies have entered clinical development, and some have now advanced to phase III clinical trials. In the coming years, one or more of these new telomerase-targeting drugs may be expected to enter the pharmacopeia of standard care. Here, we briefly review the molecular functions of telomerase in cancer and provide an update about the preclinical and clinical development of telomerase targeting therapeutics. View Full-Text
Keywords: telomeres; telomerase; targeted therapy telomeres; telomerase; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Xu, Y.; Goldkorn, A. Telomere and Telomerase Therapeutics in Cancer. Genes 2016, 7, 22.

AMA Style

Xu Y, Goldkorn A. Telomere and Telomerase Therapeutics in Cancer. Genes. 2016; 7(6):22.

Chicago/Turabian Style

Xu, Yucheng, and Amir Goldkorn. 2016. "Telomere and Telomerase Therapeutics in Cancer" Genes 7, no. 6: 22.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop